Reema Syed, MD
Ophthalmology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 33
- 8 carriers
- Office
- 1
Offices
1 location · Retinal Diagnostic Center A Medical Corporation · 6 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
33 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Syed’s office at (408) 559-0666 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
33 of 33 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A149699 · Current
Licensed to practise in California · since 2017 · expires 2027-05-31 · Aga Khan University, Aga Khan Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$1,038,558
Medicare paid this office $1,038,558 for 741 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 130 | $530,064 | None |
| Injection of drug into eye | 251 | $74,514 | $103 |
| Injection, ranibizumab, 0.1 mg | 57 | $59,760 | None |
| Established patient complete exam of visual system | 421 | $59,520 | $108 |
| Imaging of retina | 717 | $51,925 | $36 |
See all 16 services
| Injection, faricimab-svoa, 0.1 mg | 130 | $530,064 | None |
| Injection of drug into eye | 251 | $74,514 | $103 |
| Injection, ranibizumab, 0.1 mg | 57 | $59,760 | None |
| Established patient complete exam of visual system | 421 | $59,520 | $108 |
| Imaging of retina | 717 | $51,925 | $36 |
| New patient visit (45+ min) | 284 | $38,149 | $134 |
| Injection, aflibercept, 1 mg | 14 | $34,040 | None |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 14 | $22,565 | None |
| Established patient problem focused exam of visual system | 184 | $19,126 | $82 |
| Compounded drug, not otherwise classified | 90 | $16,067 | None |
| Destruction of leaking blood vessels of retina using laser | 36 | $15,481 | $323 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 12 | $13,531 | $1,128 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 64 | $10,643 | $159 |
| Photocoagulation treatment to prevent detachment of retina | 24 | $6,395 | $228 |
| 2d ultrasound scan of eye tissue and structures | 72 | $4,221 | $43 |
| Photography of the retina | 36 | $1,160 | $29 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
741 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 14% · Women 58% · Also on Medicaid 48% · Health risk score 1.55. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 53% · Chronic kidney disease 28% · Coronary heart disease 22% · Heart failure 17% · Depression 15% · Atrial fibrillation 14% · Cancer 9% · COPD 8% · Stroke 7% · Dementia 6%.
The office billed $3,915,843, Medicare allowed $1,320,329 and paid $1,038,558; for 24,405 services of 43 kinds; $697,550 of it was for drugs given in the office and $341,008 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 741 | 24,405 | 74 | 1.55 | $3,915,843 | $1,038,558 |
| 2023 | 17 | 91 | 63 | 2.17 | $42,241 | $10,755 |
| 2021 | 13 | 38 | 65 | 2.47 | $14,037 | $2,823 |
| 2019 | 13 | 17 | 70 | 1.48 | $22,631 | $1,709 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Imaging of retina | 11 | $253 | $17 |
2021: 1 service
| Short return visit (20+ min) | 12 | $1,031 | $54 |
Medicaid work
$392,857 in 2024
Medicaid paid $392,857 for 3,409 billed services this clinician did in 2024, up to 149 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Injection, faricimab-svoa, 0.1 mg | 173 | $192,212 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 621 | $39,816 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,184 | $30,845 |
| TREATMENT X10SV RETINOPATHY | 107 | $27,266 |
| New patient visit (45+ min) | 202 | $22,548 |
| Return visit (30+ min) | 158 | $20,937 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 372 | $20,805 |
| Injection, bevacizumab, 10 mg | 262 | $12,837 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 159 | $8,767 |
| Ranibizumab injection | 27 | $8,490 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 53 | $6,589 |
| OPH US DX B-SCAN | 31 | $913 |
| 2024 | 3,409 | 13 | 149 | $392,857 |
| 2023 | 133 | 5 | 15 | $16,120 |
| 2022 | 55 | 3 | 14 | $7,621 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 53 | $12,023 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 12 | $1,264 |
| Short return visit (20+ min) | 16 | $1,070 |
| Compounded drug, not otherwise classified | 14 | $952 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 38 | $811 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 25 | $6,237 |
| Short return visit (20+ min) | 13 | $1,070 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 17 | $314 |
Drugs they prescribed that Part D paid
$16,839
Pharmacies billed $16,839 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 314) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
206 generic and 108 brand-name prescriptions · $16,839 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Bromfenac | 27 | $3,617 | $134 |
| Prednisolone Acetate | 68 | $2,738 | $40 |
| Ketorolac Tromethamine | 40 | $1,503 | $38 |
| Cyclosporine | 14 | $1,281 | $92 |
| Brimonidine | 46 | $1,262 | $27 |
See all 7 drugs
| Bromfenac | 27 | $3,617 | $134 |
| Prednisolone Acetate | 68 | $2,738 | $40 |
| Ketorolac Tromethamine | 40 | $1,503 | $38 |
| Cyclosporine | 14 | $1,281 | $92 |
| Brimonidine | 46 | $1,262 | $27 |
| Dorzolamide-Timolol | 30 | $521 | $17 |
| Latanoprost | 32 | $420 | $13 |
Year by year
| 2024 | 314 | 117 | 0% (0) | 34% | $16,839 |
| 2023 | 651 | 162 | 0% (0) | 22% | $62,059 |
| 2022 | 621 | 147 | 0% (0) | 34% | $40,846 |
| 2021 | 319 | 93 | 0% (0) | 31% | $18,338 |
| 2020 | 167 | 64 | 0% (0) | 25% | $15,248 |
| 2019 | 104 | 47 | 0% (0) | 36% | $7,514 |
| 2018 | 95 | 34 | 0% (0) | 45% | $18,365 |
| 2017 | 58 | 23 | 0% (0) | None | $1,448 |
| 2016 | 78 | 15 | 0% (0) | None | $1,362 |
| 2015 | 25 | None | 0% (0) | None | $500 |
| 2014 | 13 | None | 0% (0) | None | $344 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Bromfenac | 84 | $16,293 | $194 |
| Prolensa | 24 | $15,265 | $636 |
| Difluprednate | 43 | $8,583 | $200 |
| Prednisolone Acetate | 73 | $3,826 | $52 |
| Cyclosporine | 23 | $2,332 | $101 |
| Ketorolac Tromethamine | 125 | $2,011 | $16 |
| Dorzolamide-Timolol | 65 | $1,220 | $19 |
| Latanoprost | 48 | $628 | $13 |
| Levobunolol | 14 | $552 | $39 |
| Erythromycin | 23 | $376 | $16 |
| Brimonidine | 27 | $348 | $13 |
| Ofloxacin | 17 | $222 | $13 |
2022: 10 drugs
| Nevanac | 26 | $10,951 | $421 |
| Prolensa | 12 | $7,809 | $651 |
| Prednisolone Acetate | 117 | $5,695 | $49 |
| Difluprednate | 29 | $3,636 | $125 |
| Ketorolac Tromethamine | 200 | $2,671 | $13 |
| Dorzolamide-Timolol | 38 | $707 | $19 |
| Latanoprost | 35 | $537 | $15 |
| Erythromycin | 30 | $422 | $14 |
| Brimonidine | 30 | $367 | $12 |
| Ofloxacin | 24 | $301 | $13 |
2021: 8 drugs
| Durezol | 20 | $4,248 | $212 |
| Prednisolone Acetate | 54 | $2,607 | $48 |
| Ketorolac Tromethamine | 96 | $1,780 | $19 |
| Latanoprost | 30 | $565 | $19 |
| Dorzolamide-Timolol | 16 | $434 | $27 |
| Brimonidine | 19 | $422 | $22 |
| Erythromycin | 20 | $270 | $14 |
| Ofloxacin | 18 | $256 | $14 |
2020: 6 drugs
| Restasis | 15 | $9,359 | $624 |
| Ketorolac Tromethamine | 28 | $812 | $29 |
| Latanoprost | 38 | $805 | $21 |
| Prednisolone Acetate | 13 | $542 | $42 |
| Dorzolamide-Timolol | 13 | $449 | $35 |
| Brimonidine | 11 | $209 | $19 |
2019: 2 drugs
| Prednisolone Acetate | 15 | $530 | $35 |
| Latanoprost | 12 | $222 | $18 |
2018: 2 drugs
| Prednisolone Acetate | 14 | $682 | $49 |
| Ketorolac Tromethamine | 14 | $210 | $15 |
2017: 2 drugs
| Latanoprost | 26 | $461 | $18 |
| Dorzolamide-Timolol | 19 | $403 | $21 |
2016: 3 drugs
| Latanoprost | 34 | $546 | $16 |
| Brimonidine | 15 | $276 | $18 |
| Timolol Maleate | 13 | $66 | $5 |
2015: 1 drug
| Latanoprost | 15 | $195 | $13 |
Money from drug and device companies
$512 in 2025
| 2025 | 5 | 13 | None | $512 |
| 2024 | 6 | 22 | None | $950 |
| 2023 | 1 | 1 | None | $128 |
| 2020 | 1 | 1 | None | $17 |
| 2019 | 2 | 2 | None | $190 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | Syfovre | $170 | 6 payments
|
| Regeneron Pharmaceuticals | None | $150 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $90 | 3 payments
|
| Genentech USA | Vabysmo | $69 | 2 payments
|
| Abbvie | Ozurdex | $32 | 1 payment
|
See all 13 published payments
| Genentech USA | Meals · 2025-11-21 | Vabysmo | $35 |
| Apellis Pharmaceuticals | Meals · 2025-11-11 | Syfovre | $31 |
| Apellis Pharmaceuticals | Meals · 2025-10-17 | Syfovre | $28 |
| Apellis Pharmaceuticals | Meals · 2025-08-22 | Syfovre | $28 |
| Regeneron Healthcare Solutions | Meals · 2025-08-19 | Eylea Hd | $26 |
| Apellis Pharmaceuticals | Meals · 2025-06-17 | Syfovre | $25 |
| Apellis Pharmaceuticals | Meals · 2025-05-14 | Syfovre | $31 |
| Regeneron Healthcare Solutions | Meals · 2025-05-07 | Eylea Hd | $34 |
| Regeneron Pharmaceuticals | Meals · 2025-04-16 | None | $150 |
| Abbvie | Meals · 2025-02-04 | Ozurdex | $32 |
| Apellis Pharmaceuticals | Meals · 2025-02-03 | Syfovre | $27 |
| Genentech USA | Meals · 2025-01-31 | Vabysmo | $34 |
| Regeneron Healthcare Solutions | Meals · 2025-01-29 | Eylea Hd | $30 |
See earlier years (2024, 2023, 2020, 2019)
2024: $950
| Astellas Pharma US | Izervay | $422 | 8 payments
|
| Abbvie | Ozurdex | $143 | 4 payments
|
| EyePoint Pharmaceuticals US | None | $125 | 1 payment
|
| Genentech USA | Vabysmo | $124 | 4 payments
|
| Apellis Pharmaceuticals | Syfovre | $104 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $31 | 1 payment
|
2023: $128
| Alimera Sciences | Yutiq | $128 | 1 payment
|
2020: $17
| Carl Zeiss Meditec | None Specified | $17 | 1 payment
|
2019: $190
| Glaukos | Istent Trabecular Micro-Bypass Stent System | $139 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $51 | 1 payment
|
Professional record
- NPI
- 1578806972
- Licence
- CA A149699California A149699: Current · expires 2027-05-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- Po Box 31309, Los Angeles, CA, 90031
- NPI first listed
- 2013-04-03
- NPI last updated
- 2021-12-08
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.